- Home
- AVD vs ADAP Comparison
AVD vs ADAP Comparison
Compare AVD & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVD
- ADAP
- Stock Information
- Founded
- AVD 1969
- ADAP 2008
- Country
- AVD United States
- ADAP United Kingdom
- Employees
- AVD N/A
- ADAP N/A
- Industry
- AVD Agricultural Chemicals
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- AVD Industrials
- ADAP Health Care
- Exchange
- AVD Nasdaq
- ADAP Nasdaq
- Market Cap
- AVD 165.8M
- ADAP 158.6M
- IPO Year
- AVD N/A
- ADAP 2015
- Fundamental
- Price
- AVD $5.28
- ADAP $0.56
- Analyst Decision
- AVD Strong Buy
- ADAP Strong Buy
- Analyst Count
- AVD 3
- ADAP 4
- Target Price
- AVD $16.67
- ADAP $2.79
- AVG Volume (30 Days)
- AVD 205.2K
- ADAP 615.0K
- Earning Date
- AVD 03-13-2025
- ADAP 03-05-2025
- Dividend Yield
- AVD 1.14%
- ADAP N/A
- EPS Growth
- AVD N/A
- ADAP N/A
- EPS
- AVD N/A
- ADAP N/A
- Revenue
- AVD $553,839,000.00
- ADAP $175,041,000.00
- Revenue This Year
- AVD N/A
- ADAP $204.91
- Revenue Next Year
- AVD $5.98
- ADAP N/A
- P/E Ratio
- AVD N/A
- ADAP N/A
- Revenue Growth
- AVD N/A
- ADAP 146.27
- 52 Week Low
- AVD $4.26
- ADAP $0.53
- 52 Week High
- AVD $14.28
- ADAP $2.05
- Technical
- Relative Strength Index (RSI)
- AVD 43.59
- ADAP 40.12
- Support Level
- AVD $5.36
- ADAP $0.55
- Resistance Level
- AVD $5.77
- ADAP $0.61
- Average True Range (ATR)
- AVD 0.25
- ADAP 0.03
- MACD
- AVD -0.08
- ADAP -0.00
- Stochastic Oscillator
- AVD 2.78
- ADAP 12.14
About AVD American Vanguard Corporation ($0.10 Par Value)
American Vanguard Corp is a United States-based diversified specialty and agricultural products company. It manufactures and formulates chemicals for crops, turf and ornamental plants, and human and animal health protection. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.